Skip to content

Effect of Gamma-oryzanol in patients with high cholesterol levels

Evaluation of Efficacy and Safety of Gamma-oryzanol in hyperlipidemia: a Randomized Double Blind Placebo Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026008
Enrollment
90
Registered
2020-06-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E780- Pure hypercholesterolemia

Interventions

Intervention1: Capsule Gamma-Oryzanol 150 mg: Capsule Gamma-Oryzanol (150 mg) twice daily orally + Standard treatment for 12 weeks Control Intervention1: Placebo capsule: Matched Placebo twice daily o

Sponsors

AP Organics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i.Age between 25 and 60 years ii.Either gender & Attending diabetic clinical at hospital. iii.Fasting serum LDL-Cholesterol > 130 mg/dl.

Exclusion criteria

Exclusion criteria: i. History of intake of dietary supplements or drugs (Retinoids, Cyclosporine, Phenothiazines) which can increase Plasma lipid level. ii. Evidence of renal disease (S. Creatinine > 1.5mg/ml) iii. Evidence of liver disease (AST/ALT >3 times of normal) iv. Pregnant and lactating mothers and women intending pregnancy v. History of alcohol intake and smoking. vi. Participation in any other clinical trial with in the last 30 days vii. History of intolerance or hypersensitivity Gamma-oryzanol. viii. Any condition which in the opinion of the PI that is significant and can make the patient unsuitable for study or can place it under additional risk, such as intolerance, allergy to Gamma-oryzanol.

Design outcomes

Primary

MeasureTime frame
Absolute changes in the fasting serum LDL-C level between the gamma-oryzanol and placebo groups from baseline to 12 weeksTimepoint: i. Baseline (0 week) ii. 12 weeks

Secondary

MeasureTime frame
Changes in the Body Mass Index (BMI) at baseline and 12 weeksTimepoint: i. Baseline (0 week) ii. 12 weeks;Changes in Total Fat Content from baseline to 12 weeks in both the groups.Timepoint: i. Baseline (0 week) ii. 12 weeks;Mean percent changes in the Total Cholesterol, Triglycerides, VLDL-C, HDL-C levels and in the LDL/HDL ratio from baseline to 12 weeks in both the groups.Timepoint: i. Baseline (0-week) ii. 12 week;To assess the adverse drug reactions in both groupsTimepoint: Throughout the study

Countries

India

Contacts

Public ContactDebasish Hota

AIIMS BHUBANESWAR

pharm_debasish@aiimsbhubaneswar.edu.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026